Alpha 2.0
Login Register
» Articles » PMID: 2049258

Subjective and Objective Assessment of Enalapril in Primary Raynaud's Phenomenon

Overview
Journal Br J Clin Pharmacol
Specialty Pharmacology
Date 1991 Apr 1
PMID 2049258
Citations 6
Authors
V F Challenor
D G Waller
R A Hayward
M J Griffin
O S Roath
Affiliations
Soon will be listed here.
Abstract

1. The efficacy and acceptability of enalapril were assessed in a double-blind, randomised, placebo controlled cross-over study in 21 patients with primary Raynaud's phenomenon. 2. Skin temperature was assessed by thermocouples in response to a 15 degrees C cold water challenge as an index of digital blood flow. 3. Following enalapril there were no significant changes in the number and severity of Raynaud's attacks, and no subjective benefit from treatment as measured by visual analogue scales, 5 point rating scales, and skin temperature response to cold challenge when compared with placebo. 4. Enalapril in a dose of 20 mg daily is ineffective in the management of primary Raynaud's phenomenon.

Citing Articles

Vasodilators for primary Raynaud's phenomenon.

Su K, Sharma M, Kim H, Kaganov E, Hughes I, Abdeen M Cochrane Database Syst Rev. 2021; 5:CD006687.

PMID: 33998674 PMC: 8127538. DOI: 10.1002/14651858.CD006687.pub4.

Oral vasodilators for primary Raynaud's phenomenon.

Stewart M, Morling J Cochrane Database Syst Rev. 2012; (7):CD006687.

PMID: 22786498 PMC: 6718219. DOI: 10.1002/14651858.CD006687.pub3.

[Raynaud phenomenon in dermatology : Part 2: therapy].

Sunderkotter C, Riemekasten G Hautarzt. 2006; 57(10):927-38.

PMID: 16964476 DOI: 10.1007/s00105-006-1218-4.

[Evidence-based therapy of Raynaud's syndrome].

Distler M, Distler J, Ciurea A, Kyburz D, Muller-Ladner U, Reich K Z Rheumatol. 2006; 65(4):285-9.

PMID: 16804699 DOI: 10.1007/s00393-006-0068-x.

[Medicinal vasoactive therapy of microcirculation disorders in rheumatoid arthritis].

Riemekasten G, Schulze-Koops H Z Rheumatol. 2005; 64(2):123-36.

PMID: 15793678 DOI: 10.1007/s00393-005-0691-y.

References
1.
Hills M, Armitage P . The two-period cross-over clinical trial. Br J Clin Pharmacol. 1979; 8(1):7-20. PMC: 1429717. DOI: 10.1111/j.1365-2125.1979.tb05903.x. View
2.
Studer A, Luscher T, Siegenthaler W, Vetter W . Captopril in various forms of severe therapy-resistant hypertension. Klin Wochenschr. 1981; 59(2):59-67. DOI: 10.1007/BF01477284. View
3.
Blunt R, Porter J . Raynaud syndrome. Semin Arthritis Rheum. 1981; 10(4):282-308. DOI: 10.1016/0049-0172(81)90006-8. View
4.
Miyazaki S, Miura K, Kasai Y, Abe K, Yoshinaga K . Relief from digital vasospasm by treatment with captopril and its complete inhibition by serine proteinase inhibitors in Raynaud's phenomenon. Br Med J (Clin Res Ed). 1982; 284(6312):310-11. PMC: 1495917. DOI: 10.1136/bmj.284.6312.310. View
5.
Havelka J, Boerlin H, Studer A, Greminger P, Tenschert W, Luescher T . Long-term experience with captopril in severe hypertension. Br J Clin Pharmacol. 1982; 14 Suppl 2:71S-76S. PMC: 1427525. DOI: 10.1111/j.1365-2125.1982.tb02060.x. View